Navigation Links
Cell Therapeutics, Inc. Announces $6.5 Million Offering
Date:11/30/2007

SEATTLE, Nov. 30 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) today announced that it has entered into agreements to sell approximately $6.5 million of its 7% Convertible Preferred Stock and warrants in a registered offering to several institutional investors, including certain of its existing securities holders. CTI will sell Series D convertible preferred stock and warrants to investors at the negotiated price of $1,000 per share of Series D convertible preferred stock. The Preferred Stock will be convertible into shares of common stock beginning on or about December 3, 2007, at a conversion price of $2.6125 per share. Purchasers will also receive warrants to purchase common stock in an amount equal to 50% of their total investment amount divided by $2.6125, which warrants will have an exercise price of $2.55 per share, which is equal to the closing bid price of the Company's common stock as reported on the NASDAQ Global Market on November 29, 2007. The warrants will not be exercisable until six months following the closing. The Company intends to use the proceeds of the offering towards the closing of its purchase of ZEVALIN(R) from Biogen Idec Inc. and for general corporate purposes.

The offering is expected to close on December 3, 2007, subject to certain closing conditions.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as the exclusive placement agent for the offering.

A shelf registration statement relating to the preferred stock and warrants to be issued in the offering has been filed with the Securities and Exchange Commission and has become effective. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our Convertible Preferred Stock or warrants. No offer, solicitation, or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. The risks and uncertainties include the risk that the above described transaction will not close as a result of the failure to meet closing conditions, investors may breach or withdraw their commitment, and until closed there is no assurance that it will close or what the total amount may be, and other risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Cell Therapeutics, Inc.

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Cell Therapeutics, Inc.

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
2. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
3. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
7. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
8. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
9. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
10. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
11. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... ... of the American Academy of Orthopaedic Surgeons , points out that therapeutic ... suffering from pain or injury. According to the report, a wider scope of ...
(Date:8/22/2017)... ... 22, 2017 , ... The old adage “you are what ... eating healthy foods. But this well-known piece of nutrition advice ignores that an ... carbohydrates—depends not only on properties of the food but also on properties of ...
(Date:8/22/2017)... del Rey, CA (PRWEB) , ... August 22, ... ... of revenue cycle management (RCM) solutions, announced recently the availability of a new ... HIM community in appreciation for their service to the healthcare industry. E/M coding ...
(Date:8/22/2017)... ... ... “Wilderness Voices”: a collection of poetry inspired by life on a Kentucky ... published author, Martha McKown, an ordained United Methodist minister with graduate degrees in Religious ... her older sisters studied High School literature. She loved the early English folk ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... is the Founder and Managing Member for t4 Leadership Development & Consulting. He ... to his definition of “success”: physician leadership development, servant leadership, data driven process ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Inc. announced today that its fully owned USA ... York City Office in Yonkers, New York ... (TWO 2 ) homecare therapy. This new East Coast location has ... under the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New ...
(Date:8/11/2017)... 11, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it will release ... and host a conference call at 9:00am ET. The ... financial results and its strategy and outlook for the ... Erez Raphael , Chief Executive Officer, and ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
Breaking Medicine Technology: